RenovoRx Inc RNXT:NASDAQ

RT Quote | NASDAQ | USD
Last | 08/09/22 EDT
2.62quote price arrow up+0.44 (+20.18%)
Volume
163,521
52 week range
1.50 - 16.74
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.62
  • 52 Week High16.74
  • 52 Week High Date08/30/21
  • 52 Week Low1.50
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap23.76M
  • Shares Out9.07M
  • 10 Day Average Volume0.04M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-45.87

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.62
  • 52 Week High16.74
  • 52 Week High Date08/30/21
  • 52 Week Low1.50
  • 52 Week Low Date05/12/22
  • Market Cap23.76M
  • Shares Out9.07M
  • 10 Day Average Volume0.04M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-45.87

RATIOS/PROFITABILITY

  • EPS (TTM)-1.00
  • P/E (TTM)-2.63
  • Fwd P/E (NTM)-2.36
  • EBITDA (TTM)-7.622M
  • ROE (TTM)-
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On RenovoRx Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing therapies for the local treatment of solid tumors and conducting a Phase III pancreatic cancer clinical trial for its lead product candidate RenovoGem. The Company’s therapy platform, RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) utilizes chemotherapeutics. RenovoTAMP combines its patented delivery system, RenovoCath, with small molecule chemotherapeutic agents, which can be...
Shaun Bagai
Chief Executive Officer, Director
James Ahlers
Chief Financial Officer, Treasurer, Company Secretary
Paul Manners
Vice President - Finance
Address
333 W Santa Clara St Ste 900
San Jose, CA
95113-1716
United States